OncoLife – Colocomprehensive panel

OncoLife – Colocomprehensive panel

Broader NGS based panel designed to meet current guidelines of targetable mutations in colon cancer and remain targeted enough to provide clinically actionable results

The patient should carry the FFPE tissue or block of the Colon. This process is carried out by Gastero Surgeon in the hospital

Patient diagnosed with Colorectal Cancer and have Family history of Colorectal Cancer. The testing helps the clinicians in guiding the use FDA-approved targeted therapies such as anti-EGFR and anti-PDL1 antibodies.

The test is performed by NGS technique & MMR by IHC

There is no risk associated with the test as biopsy will be taken by the trained surgeon in the hospital under anasthesia

The test is reported as pathogenic mutation detected (Positive) No pathogenic variants detected (Negative) and Inconclusive Variant of uncertain clinical significance detected